Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Infectious Disease

Building Your Care Team and Monitoring Your Health

At a Glance

Managing Kaposi sarcoma requires a multidisciplinary care team, including an infectious disease doctor, oncologist, and dermatologist. Long-term care involves monitoring immune health, routine skin checks every 3 to 6 months, and managing complications like lymphedema.

Kaposi sarcoma (KS) is a chronic condition that requires more than just a single doctor; it requires a coordinated team of specialists [1][2]. Because KS is driven by both a virus and your immune system’s health, your care team must address the tumor and the underlying cause simultaneously [3][4].

Building Your Multidisciplinary Care Team

A “multidisciplinary team” means that specialists from different fields work together to create a single, cohesive plan for you [1][5]. Your “roster” should ideally include:

  • Infectious Disease (ID) / HIV Specialist: If you have Epidemic (AIDS-related) KS, this doctor is the lead for managing your antiretroviral therapy (ART) and monitoring your immune health (CD4 counts and viral load) [3][4].
  • Medical Oncologist: This specialist manages systemic treatments like chemotherapy (e.g., liposomal doxorubicin) or immunotherapy if the disease is advanced or affecting internal organs [3][6].
  • Dermatologist: A skin expert who provides local treatments (like laser or surgery) and monitors your skin lesions for changes in size, color, or texture [7][8].
  • Lymphedema Specialist / Physical Therapist: Many KS patients experience chronic swelling (lymphedema) [9]. A therapist trained in manual lymphatic drainage and compression therapy is essential for maintaining mobility and comfort [9][10].
  • Mental Health Professional / Counselor: Because dealing with visible lesions and the need for chronic monitoring can be highly stressful, a therapist or counselor is a critical part of your team to help manage anxiety and depression [11].

Vetting Your Specialists

Because KS is a rare disease, it is important to ensure your doctors have specific expertise. You can “vet” a new specialist by asking:

  1. “How often do you treat my specific subtype of KS?” Experience with Classic KS is different from experience with AIDS-related or transplant-related KS.
  2. “How do you coordinate with the other members of my team?” A doctor who works in a vacuum may miss important shifts in your immune health [1][2].
  3. “Are you familiar with LANA-1/HHV-8 testing for diagnosis and monitoring?” This is the gold standard for accurately identifying KS [12][5].

Life After Diagnosis: Monitoring and Surveillance

Even when your KS is stable or in remission, regular follow-ups are necessary to catch any changes early. Current guidelines (such as NCCN) recommend a structured surveillance plan [4]:

  • Physical Exams: Usually every 3 to 6 months [4]. Your doctor will perform a “head-to-toe” skin check and look in your mouth for any new purple or red patches [7].
  • Blood Work: Regular monitoring of CD4 counts and viral loads (for HIV-related KS) or drug levels (for transplant-related KS) to ensure your immune system remains stable [3][13].
  • Imaging: Scans like CT or PET/CT are not typically done for everyone; they are usually reserved for patients who had internal (visceral) disease or those experiencing new symptoms like a persistent cough or abdominal pain [4][14].

Survivorship and Quality of Life

Living with KS involves managing both the physical and emotional aspects of the disease.

  • Managing Lymphedema: Swelling in the legs or face can persist even after the tumors are gone [9]. Consistent use of compression garments and specialized massage can prevent the swelling from becoming permanent or painful [9][15].
  • Appearance of Lesions: Some lesions may leave behind flat, brownish stains (hyperpigmentation) even after successful treatment [16]. A dermatologist can discuss cosmetic options if these are a source of distress.
  • The Psychological Toll: “Scanxiety”—the fear that comes before a follow-up appointment—is very real [11]. For those with chronic HIV or transplants, the burden of lifelong monitoring can be heavy. Don’t hesitate to lean on the mental health professional on your team [11].
Component Standard Surveillance Schedule Goal
Skin/Oral Exam Every 3–6 months Detect new or changing lesions [4]
Immune Labs Based on ID/Transplant specialty Ensure immune suppression is controlled [13]
Imaging (CT/PET) Only if symptoms arise Check for internal (visceral) spread [4]
Lymphedema Care Ongoing / As needed Manage swelling and maintain mobility [9]

Common questions in this guide

Which specialists should be on my Kaposi sarcoma care team?
Your care team should typically include an infectious disease or HIV specialist, a medical oncologist, and a dermatologist. Many patients also benefit from working with a lymphedema specialist and a mental health professional for comprehensive support.
How often do I need follow-up exams for Kaposi sarcoma?
Standard surveillance usually involves full physical skin and oral exams every three to six months. Your doctor will also order regular blood work to monitor your immune system health based on your specific type of KS.
Will I need regular CT or PET scans for Kaposi sarcoma?
Routine imaging scans are not typically required for everyone with KS. They are generally reserved for patients who have a history of internal disease or those developing new symptoms, such as an unexplained persistent cough or abdominal pain.
How can I manage chronic swelling or lymphedema from Kaposi sarcoma?
Swelling, known as lymphedema, can be managed through the consistent use of compression garments and specialized manual lymphatic drainage massage. Working with a physical therapist trained in lymphedema care can help maintain your mobility and comfort.
What should I look for when monitoring my KS at home?
Between doctor visits, you should check your skin from head to toe and look inside your mouth for any new purple or red patches. You should also watch for changes in the size, color, or texture of any existing lesions and report them to your dermatologist.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with my specific subtype of Kaposi sarcoma (e.g., Classic vs. Epidemic) do you currently manage?
  2. 2.Do you have a direct line of communication with my [Infectious Disease specialist/Oncologist/Dermatologist] to coordinate my immune health and tumor treatment?
  3. 3.What is your long-term plan for monitoring for internal (visceral) disease, and what symptoms should I watch for at home?
  4. 4.If I develop chronic swelling (lymphedema), do you have a specialized physical therapist you recommend?
  5. 5.What criteria will you use to determine if I am in 'remission' versus having 'stable disease'?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Kaposi's Sarcoma. A Case Report.

    Polách O, Kopecký A, Wandrolová Z, et al.

    Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti 2024; (80(2)):114-118 doi:10.31348/2024/16.

    PMID: 38531684
  2. 2

    De Novo Kaposi Sarcoma in an HIV-Negative Liver Transplant Recipient With Ulcerative Colitis and Primary Sclerosing Cholangitis.

    Ramakrishnan P, Amin K, Gaertner W, Aby ES

    Case reports in transplantation 2024; (2024()):4699128 doi:10.1155/crit/4699128.

    PMID: 39624666
  3. 3

    Cost-effectiveness protocol for treating adult HIV-infected patients with Kaposi sarcoma in resource-limited settings: a phase III, randomized, open-label, non-inferiority study of paclitaxel and pegylated liposomal doxorubicin.

    Chapola JC, Kleber SL, Krown SE, Painschab M

    Cost effectiveness and resource allocation : C/E 2025; (23(1)):78 doi:10.1186/s12962-025-00677-x.

    PMID: 41286911
  4. 4

    AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

    Reid E, Suneja G, Ambinder RF, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2019; (17(2)):171-189.

    PMID: 30787130
  5. 5

    A Case of Non-cutaneous Kaposi Sarcoma.

    Osei N, Fletcher G, Showunmi A, Ahluwalia M

    Cureus 2022; (14(12)):e32394 doi:10.7759/cureus.32394.

    PMID: 36636532
  6. 6

    Update on oncogenesis and therapy for Kaposi sarcoma.

    Dupin N

    Current opinion in oncology 2020; (32(2)):122-128 doi:10.1097/CCO.0000000000000601.

    PMID: 31815777
  7. 7

    Electrochemotherapy in Kaposi's Sarcoma Patients: From the Gold Standard Strategy to Locally Advanced Cutaneous and Subcutaneous Lesions.

    Rullo V, Castellaneta F, D'Antonio S, et al.

    Cancers 2024; (16(7)) doi:10.3390/cancers16071295.

    PMID: 38610972
  8. 8

    Laser Therapy Approaches in the Treatment of Kaposi's Sarcoma: A Comprehensive Review of Dermatologic Options.

    Battilotti C, Cassalia F, Svara F, et al.

    Dermatology practical & conceptual 2025; (15(3)) doi:10.5826/dpc.1503a5332.

    PMID: 40790410
  9. 9

    Lymphedema and Kaposi sarcoma: A narrative review.

    Dauguet M, Lebbé C, Vignes S

    Journal de medecine vasculaire 2023; (48(5-6)):181-187 doi:10.1016/j.jdmv.2023.10.007.

    PMID: 38035924
  10. 10

    AIDS-Related Kaposi Sarcoma Associated with Steroid-Unresponsive Periorbital Lymphedema that Responded to Chemotherapy.

    Zeng Y, Prasad R, King RD, et al.

    The American journal of case reports 2023; (24()):e938801 doi:10.12659/AJCR.938801.

    PMID: 36879523
  11. 11

    Randomized Phase IIA Trial of Gemcitabine Compared With Bleomycin Plus Vincristine for Treatment of Kaposi's Sarcoma in Patients on Combination Antiretroviral Therapy in Western Kenya.

    Busakhala NW, Waako PJ, Strother MR, et al.

    Journal of global oncology 2018; (4()):1-9 doi:10.1200/JGO.17.00077.

    PMID: 30241150
  12. 12

    A Series of Patients with Kaposi Sarcoma (Mediterranean/Classical Type): Case Presentations and Short Update on Pathogenesis and Treatment.

    Temelkova I, Tronnier M, Terziev I, et al.

    Open access Macedonian journal of medical sciences 2018; (6(9)):1688-1693 doi:10.3889/oamjms.2018.354.

    PMID: 30337990
  13. 13

    Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study.

    Delyon J, Rabate C, Euvrard S, et al.

    Journal of the American Academy of Dermatology 2019; (81(2)):448-455 doi:10.1016/j.jaad.2019.03.028.

    PMID: 30902727
  14. 14

    Pleural Kaposi Sarcoma in Two HIV-Positive Patients.

    Abou Hamdan D, Hayek G, Abi Hanna P, et al.

    Cureus 2024; (16(7)):e64938 doi:10.7759/cureus.64938.

    PMID: 39156295
  15. 15

    Disseminated Kaposi's sarcoma as a presenting sign of HIV in an Indian male: A case report with dermoscopic findings.

    Prabhakaran N, Gupta D, Chandrashekhar L, et al.

    Indian journal of sexually transmitted diseases and AIDS 2020; (41(1)):102-105 doi:10.4103/ijstd.IJSTD_53_16.

    PMID: 33062993
  16. 16

    An unusual series of patients with Kaposi sarcoma.

    Wang J, Reid H, Klimas N, Koshelev M

    JAAD case reports 2019; (5(8)):646-649 doi:10.1016/j.jdcr.2019.05.016.

    PMID: 31388528

This page is for informational purposes only and does not replace professional medical advice. Always consult your multidisciplinary care team regarding your specific Kaposi sarcoma monitoring and treatment plan.

Get notified when new evidence is published on Kaposi sarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.